{"organizations": [], "uuid": "b204cf5a87f70525cb1afcdc98f1aa0752ebdc63", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-lilly-receives-additional-fda-appr/brief-lilly-receives-additional-fda-approval-for-verzeniotm-as-initial-treatment-for-advanced-breast-cancer-idUSASB0C7JH", "country": "US", "domain_rank": 408, "title": "BRIEF-Lilly Receives Additional FDA Approval For Verzeniotm, As Initial Treatment For Advanced Breast Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-26T23:31:00.000+02:00", "replies_count": 0, "uuid": "b204cf5a87f70525cb1afcdc98f1aa0752ebdc63"}, "author": "", "url": "https://www.reuters.com/article/brief-lilly-receives-additional-fda-appr/brief-lilly-receives-additional-fda-approval-for-verzeniotm-as-initial-treatment-for-advanced-breast-cancer-idUSASB0C7JH", "ord_in_thread": 0, "title": "BRIEF-Lilly Receives Additional FDA Approval For Verzeniotm, As Initial Treatment For Advanced Breast Cancer", "locations": [], "entities": {"persons": [{"name": "initi", "sentiment": "negative"}, {"name": "eli lilly", "sentiment": "none"}, {"name": "verzenio", "sentiment": "none"}, {"name": "lilly", "sentiment": "none"}], "locations": [], "organizations": [{"name": "fda approval for verzeniotm", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "eli lilly and co", "sentiment": "none"}, {"name": "treatment for advanced breast cancer reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 32 PM / Updated 6 minutes ago BRIEF-Lilly Receives Additional FDA Approval For Verzeniotm, As Initial Treatment For Advanced Breast Cancer Reuters Staff Feb 26 (Reuters) - Eli Lilly And Co: * LILLY RECEIVES ADDITIONAL FDA APPROVAL FOR VERZENIOTM (ABEMACICLIB), AS INITIAL TREATMENT FOR ADVANCED BREAST CANCER * ELI LILLY AND CO - ‍NEW INDICATION BASED ON MONARCH 3 TRIAL CAN HELP MORE WOMEN LIVING WITH HR+, HER2- ADVANCED BREAST CANCER​ * ELI LILLY - ‍RECOMMENDED DOSE OF VERZENIO IN COMBINATION WITH AI IS 150 MG ORALLY TWICE DAILY, CONTINUED UNTIL DISEASE PROGRESSION/ UNACCEPTABLE TOXICITY​ * ELI LILLY AND CO - ‍VERZENIO IS AVAILABLE IN 4 TABLET STRENGTHS (200 MG, 150 MG, 100 MG, AND 50 MG)​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-26T23:31:00.000+02:00", "crawled": "2018-02-26T23:43:27.001+02:00", "highlightTitle": ""}